Association between Thymic Function and Allogeneic Hematopoietic Stem Cell Transplantation Outcome: Results of a Pediatric Study  by Saglio, Francesco et al.
Biol Blood Marrow Transplant 21 (2015) 1099e1105Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgAssociation between Thymic Function and Allogeneic
Hematopoietic Stem Cell Transplantation Outcome: Results
of a Pediatric StudyFrancesco Saglio 1,*, Silvia Cena 2, Massimo Berger 1, Paola Quarello 1, Viola Boccasavia 2,
Federica Ferrando 2, Laura Pittana 1, Benedetto Bruno 2, Franca Fagioli 1
1 Pediatric Onco-Hematology, Stem Cell Transplantation, and Cellular Therapy Division, A.O.U. Citta’ della Salute e della Scienza di Torino, Ospedale Infantile Regina
Margherita, Torino, Italy
2Division of Hematology, A.O.U. Citta’ della Salute e della Scienza di Torino, Presidio Molinette, University of Torino and Department of Molecular Biotechnology and
Health Sciences, University of Torino, Torino, ItalyArticle history:
Received 14 August 2014
Accepted 10 February 2015
Key Words:
sjTREC
Allogeneic hematopoietic stem
cell transplantation
PediatricFinancial disclosure: See Acknowle
* Correspondence and reprint re
Onco-Hematology, Stem Cell Tran
sion, A.O.U. Citta’ della Salute e de
Regina Margherita, Piazza Polonia
E-mail address: francesco.saglio
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
Robust T cell function recovery has been shown to be crucial in determining allogeneic hematopoietic stem
cell transplantation (HSCT) outcome, and there is growing evidence that the thymus plays a central role in
regulating this process. We performed a long-term analysis of the role of thymic activity recovery in a
population of pediatric patients undergoing allogeneic HSCT by signal joint T cell receptor excision circle
(sjTREC) quantiﬁcation. In this study, characterized by a long-term follow-up (median, 72 months), we found
patients with higher levels of sjTRECs before transplantation had a statistically signiﬁcant reduced risk of
death compared with patients with lower values (relative risk, .31; 95% conﬁdence interval, .30 to .32; P ¼
.02), showing this different outcome was mainly related to a reduction of relapse incidence (14% versus 43%,
P ¼ .02). Unlike previous reports, we observed no correlation between sjTREC levels and lymphocyte recovery.
Moreover, we conﬁrmed that only graft-versus-host disease inﬂuenced thymic activity after transplantation.
In conclusion, our results suggest an association between pretransplantation thymic activity and the long-
term outcome of pediatric patients undergoing HSCT, mainly through a reduction of relapse opportunities.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cells transplantation
(alloHSCT) is 1 of the best therapeutic options available for
pediatric patients affected by various malignant diseases and
other nonmalignant disorders involving the hematopoietic
system [1]. T lymphocyte function recovery is a crucial event
indetermining theprognosis of patientsundergoingalloHSCT
because its prolonged impairment may be related to the
occurrence of infectious complications and, in the malignant
setting, also to the recurrence of primary disease [2,3].
T cell recovery after alloHSCT typically evolves throughout
2 distinct phases, called thymus-independent, or early
phase, and thymus-dependent, or late phase. The thymus-
independent phase consists of the peripheral expansion ofdgments on page 1104.
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ty for Blood and Marrow Transplantation.mature T cells transferred to the patient with the graft [4,5].
The thymus-dependent phase consists of the generation of
new naive T cells from the donor-derived hematopoietic
progenitors occurring in the recipient’s thymus. The thymus-
dependent phase accounts for the most durable reconstitu-
tion of the T cell compartment, generates T cell receptor
repertoire diversity [6], and requires a functionally active
thymus [7].
Thymic function can be evaluated through the evaluation
of the signal joint T cell receptor excision circles (sjTRECs) by
quantitative PCR. sjTRECs are episomal DNA fragments
resulting from the deletion of the T cell receptor d region
during T cell receptor a locus rearrangement. Because they
cannot replicate and are not duplicated, they are diluted out
during cell division, allowing a direct evaluation of recent
thymic output [8,9].
Previous studies explored the relationship between
sjTREC levels and the kinetics of the phenotypic and func-
tional changes in peripheral T cells after alloHSCT, showing a
direct correlation between sjTREC levels and the percentage
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covery pathway in both adult [10,11] and pediatric [10-12]
patients. sjTREC levels have also been associated with ma-
jor parameters affecting the transplantation outcome, such
as the incidence of acute and chronic graft-versus-host dis-
ease (GVHD) [13,14], opportunistic infections [7,13], and
relapse [15,16], but all these studies focused on a single
parameter, in a single setting at a single time point [17], and
in mixed (pediatric and adult) populations. In this study, we
conducted a long-term comprehensive analysis of the impact
of sjTRECs on main transplantation outcome variables in a
homogenous pediatric population undergoing alloHSCT.METHODS
Patients
The study population included 57 patients (38 males and 19 females)
aged from 0 to 22 years (median age, 9 years) who underwent alloHSCT
between April 2006 and October 2008 at our center. To exclude possible bias
related to a too-short observation period, analyses were performed when
most patients reached a median follow-up of over 5 years. The Institutional
Committee onMedical Ethics approved this study, and patients or their legal
representatives provided informed consent. Patient characteristics, condi-
tioning regimens, hematopoietic stem cell sources, donor characteristics,
and GVHD prophylaxes are summarized in Table 1.
Donor selection and HLA typing were performed according to the Italian
Bone Marrow Donor Registry Standard of Practice. In the analyses, total
nucleated cell and CD34þ cell values were expressed in percentiles and
quartiles according to their non-Gaussian distribution. PretransplantationTable 1
Patient and HSCT Characteristics
Characteristic Subcategory n Percent
Sex Male 38 67
Female 19 33
Disease ALL 23 40
AML 8 14
Inborn errors 6 10
Solid tumors 6 10
Lymphoma 5 9
MDS and JMML 4 7
HLH 2 3.5
SAA 2 3.5
CML 1 1
Phase* Early 8 17
Advanced 39 83
Comorbidity score (18) 0 44 79
1-2 13 23
3þ 0
Conditioning regimen TBI based 31 54
Bu based 13 23
Others 13 23
HSC source BM 46 81
CB 8 14
PBSC 3 5
Donor Sibling 21 37
MUD 17 30
MMUD 11 19
CB 8 14
GVHD prophylaxis CyA-MTX-ATG 27 48
CyA 12 21
CyA-MTX 8 14
CyA-ATG-MMF 4 7
CyA-ATG-PDN 3 5
Others 3 5
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leu-
kemia; MDS, myelodysplasia; JMML, juvenile myelomonocytic leukemia;
HLH, hemophagocytic lymphohistiocytosis; SAA, severe aplastic anemia;
CML, chronic myelogenous leukemia; TBI, total body irradiation; Bu,
busulfan; BM, bone marrow; CB, cord blood; PBSC, peripheral blood stem
cell; MUD, matched unrelated donor; MMUD, mismatched unrelated donor;
CyA, cyclosporine; MTX, methotrexate; ATG, antithymocyte globulin; MMF,
mycophenolate mofetil; PDN, prednisone.
* For malignant diseases only.comorbidities were scored according to a previously reported classiﬁcation
for pediatric patients [18]. Thepatients underwent clinical andhematological
post-transplantation assessments according to our center’s policy. Complete
blood counts were performed daily until hematological recovery, twice a
weekuntil dayþ100, and according topatients’ clinical conditions thereafter.
Acute and chronic GVHD were diagnosed and classiﬁed according to
previously reported criteria [19,20]. To monitor patients for viral compli-
cations, cytomegalovirus, Epstein-Barr virus, and adenovirus PCR were
performed weekly on peripheral blood.
sjTREC Frequency Evaluation
The day before starting the conditioning regimen, on days 90  7, 180 
7, and 365  7, patients were evaluated for sjTREC frequency according to
previously reported methods [21,22] on peripheral blood mononuclear cells
(PBMC) by real-time quantitative PCR (TaqMan Technology, Applied Bio-
system, Foster, CA). The primer TREC sequences and probes used were as
follows: forward, 50-TGGTTTTTGTGCCCAC-30; reverse, 50-GTGCCAGCTG-
CAGGGTTT-30; probe, 50(FAM) CATAGGCACCTGCACCCCGTGC (TAMRA) P-30 .
PCR conditions were as follows: 2 minutes at 50C, 10 minutes at 95C
followed by 45 cycles of ampliﬁcation (95C for 15 seconds, 60C for 1
minute). To obtain absolute sjTREC quantiﬁcation, we prepared a standard
curve by using 5 different concentrations of a PCR2-1TA plasmid encoding
the sjTREC sequence. PCR was performed using the ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems, Foster City, CA), and data
obtained were analyzed using SDS.2 software (Applied Biosystems). sjTREC
values are expressed as copy number/100 ng DNA from PBMCs. Because the
non-Gaussian distribution of sjTREC values and almost all patients enrolled
in this study had median sjTREC values under the median value of age-
matched control subjects at all time points, all analyses were performed
considering sjTREC percentiles and quartiles of the study population.
Deﬁnitions and Outcome Endpoints
The primary endpoint of this study was the assessment of the impact of
sjTREC levels on the overall survival (OS) rates in a population of pediatric
patients undergoing HSCT. Secondary endpoints were the assessment of
sjTREC levels on both transplant-related mortality (TRM) and relapse inci-
dence (RI) and the identiﬁcation of transplant-related factors able to inﬂu-
ence sjTREC levels. OS was deﬁned as the probability of survival irrespective
of the disease state at any point in time. If, at the end of the study time, the
patient was still alive, data were censored at the last follow-up date.
TRM was deﬁned as the probability of dying without a previous relapse
occurrence. If the patient either experienced relapse or was still alive at the
end of the study time, data were censored at the relapse date or at last
follow-up date, respectively. For malignant diseases, RI was deﬁned as the
probability of having had a relapse. If the patient either died without
experiencing relapse or was still alive at the end of the study time, datawere
censored at the date of death or at the last follow-up date, respectively. For
malignancies, patients not in a ﬁrst complete remission at the time of
transplant and patients who had previously failed at least 1 ﬁrst-line
treatment were considered to be in an advanced disease phase, whereas
all other patients were considered to be in an early disease phase.
Chimerism and Immune Recovery Evaluation
Donor chimerism was determined at þ30  7 and þ60  7 days after
alloHSCT on whole bone marrow mononuclear cells and at þ180  7
and þ365  7 days on PBMCs by quantitative PCR of informative short
tandem repeats in the recipient and donor, according to a previously
described method [23]. Absolute lymphocyte numbers were obtained from
complete blood count analyses and compared with normal values according
to patient age [24]. Lymphocyte recovery was deﬁned as the ﬁrst of 3
consecutive days with an absolute lymphocyte count over the ﬁfth
percentile of normal values for the patient’s age. In a subset of patients, we
also investigated speciﬁc lymphocyte subpopulation recovery at þ180 days
and þ365 days by ﬂow cytometry. Helper T cell (CD3þCD4þ), cytotoxic T cell
(CD3þCD8þ), natural killer cell (CD16þCD56þ), and B cell (CD19þCD20þ)
recovery was deﬁned as the presence of an absolute number of cells over the
ﬁfth percentile of normal values according to patient age [24].
Statistical Analysis
OS was calculated according to the Kaplan-Meier method, and the sig-
niﬁcance between the observed differences was established by the log-rank
test [25]. The multivariate analysis on OS was performed using Cox’s
method.
TRM and relapse rate were calculated as a cumulative incidence to
adjust the analysis for competing risks: relapse and transplant-related death
were considered competing risks, respectively. The differences in terms of
cumulative incidence were compared using Gray’s test. To assess the in-
ﬂuence of different transplant-related variables on sjTREC levels, a 2-tailed
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perform multivariate analyses we selected variables reaching P < .1 in the
univariate analyses. All statistical analyses were performed using SPSS (IBM
Corp., Armonk, NY), NCSS (NCSS PASS, Number Crunched Statistical System,
Kaysville, UT), and R 2.5.0 (www.r-project.org) software packages.RESULTS
sjTREC Frequency
Median sjTREC values were 16 (range, 0 to 1684), 1 (range,
0 to 160),14 (range, 0 to553), and201 (range, 0 to 1006) sjTREC
copies/100 ng DNA before HSCT, at day þ90, at day þ180, and
at day þ365, respectively. To identify transplant-related fac-
tors associatedwith the frequencyof sjTRECs,weevaluatedthe
impact of different variables on median sjTREC values, before
HSCT and then at different time points (Table 2).Table 2
sjTREC Frequency
Characteristic No. of Patients with
sjTREC Level <
Median Value of the
Study Population
No. of Patients with
sjTREC Level >
Median Value of the
Study Population
P
Pre-HSCT (n ¼ 57)
Age .04
0-5 yr (n ¼ 15) 6 (40%) 9 (60%)
6-8 yr (n ¼ 11) 3 (27%) 8 (73%)
9-14 yr
(n ¼ 16)
8 (50%) 8 (50%)
>14 yr (n ¼ 15) 8 (53%) 7 (47%)
Disease .03
Malignant
(n ¼ 47)
28 (60%) 19 (40%)
Nonmalignant
(n ¼ 10)
2 (20%) 8 (80%)
Comorbidities (18) .21
0 (n ¼ 44) 21 (48%) 23 (52%)
1-2 (n ¼ 13) 9 (70%) 4 (30%)
Disease phase* .005
Early (n ¼ 8) 1 (12%) 7 (88%)
Advanced
(n ¼ 39)
27 (69%) 12 (31%)
Time from
diagnosis
to HSCT
.57
<6 mo (n ¼ 25) 16 (64%) 9 (36%)
>6 mo (n ¼ 22) 12 (54%) 10 (46%)
Day þ90 (n ¼ 57)
ATG .02
Yes (n ¼ 37) 25 (68%) 12 (32%)
No (n ¼ 20) 5 (25%) 15 (75%)
Viral infection .01
Yes (n ¼ 30) 21 (70%) 9 (30%)
No (n ¼ 27) 9 (33%) 18 (67%)
Day þ 180 (n ¼ 57)
Grades II-IV acute
GVHD
.03
Yes (n ¼ 21) 15 (71%) 6 (29%)
No (n ¼ 36) 16 (44%) 20 (56%)
Day þ 365 (n ¼ 43)
Age .03
0-5 yr (n ¼ 9) 3 (33%) 6 (64%)
6-8 yr (n ¼ 10) 3 (30%) 7 (70%)
9-14 yr
(n ¼ 14)
7 (50%) 7 (50%)
>14 yr (n ¼ 10) 9 (90%) 1 (10%)
Chronic GVHD .02
Yes (n ¼ 6) 6 (100%) 0
No (n ¼ 37) 16 (43%) 21 (57%)
Viral infection .03
Yes (n ¼ 24) 16 (67%) 8 (33%)
No (n ¼ 19) 6 (32%) 13 (68%)
* For malignant diseases only.Overall Survival
As of March 2014, the median follow-up time of patients
who were still alive was 72 months (range, 42 to 90). The OS
rate at 7 years of the entire study population was 70% (95%
conﬁdence interval [CI], 58% to 82%). We found a statistically
signiﬁcant relationship between sjTREC frequency before
transplantation and 7-year OS. Patients with sjTREC values
below the 50th percentile of the study population before
HSCT had an OS rate of 56% (95% CI, 38% to 73%), whereas
patients with sjTRECs above the 50th percentile had an OS
rate of 85% (95% CI, 71% to98%) (P¼ .02) (Table 3 and Figure 1).
Moreover, before transplantation, itwas possible to performa
more extended analysis considering the sjTREC frequency
subgrouped into quartiles: patients with sjTREC values in the
ﬁrst, second, third, and fourth quartiles had OS rates of 40%Table 3
Overall Survival
Variable n Events 7-yr OS 95% CI Log Rank
Test, P
sjTRECs pre-HSCT
<50th percentile 30 13 56% (38-73) .02
>50th percentile 27 4 85% (71-98)
sjTRECs þ90 days .97
<50th percentile 30 9 70% (54-86)
>50th percentile 27 8 70% (52-88)
sjTRECs þ180 days .1
<50th percentile 29 7 60% (42-78)
>50th percentile 25 8 80% (66-94)
sjTRECs þ365 days .6
<50th percentile 20 4 77% (59-95)
>50th percentile 18 6 83% (65-100)
Sex .035
Male 38 15 60% (44-76)
Female 19 2 89% (75-100)
Age .28
0-5 yr 15 5 63% (36-90)
6-8 yr 11 4 64% (36-91)
9-14 yr 16 2 87% (71-100)
>15 yr 15 6 60% (34-85)
Disease .14
Malignant 47 16 65% (53-81)
Nonmalignant 10 1 90% (63-100)
Comorbidity score <.0001
Low-risk group 44 7 84% (83-84)
Intermediate-risk
group
13 10 23% (0-46)
Disease phase* .04
Early 8 0 100%
Advanced 39 16 60% (44-76)
Time between
diagnosis and
HSCT*
.55
<6 mo 25 7 73% (56-90)
>6 mo 22 9 60% (40-80)
TBI .51
Yes 31 8 73% (57-89)
No 26 9 65% (47-83)
HSC source .27
BM 46 16 65% (51-79)
PBSC 3 1 87% (63-100)
CB 8 0 100%
TNCs .65
<50th percentile 29 9 69% (51-87)
>50th percentile 28 8 71% (53-89)
CD34þ cells .78
<50th percentile 30 9 70% (54-86)
>50th percentile 27 8 69% (51-87)
TNCs indicates total nucleated cells.
All variables potentially able to inﬂuence OS were evaluated: sjTREC levels
before alloHSCT, patient’s sex, comorbidities, and disease phase showed a
statistically signiﬁcant (P < .05) correlation with OS.
* For malignant diseases only.
Figure 1. OS according to sjTREC levels. Patients with sjTRECs over the 50th
percentile before HSCT (continuous line) showed a statistically signiﬁcant
increased survival rate compared with patients with sjTRECs under the 50th
percentile (dotted line) at same time point.
Table 4
TRM Univariate Analysis
Variable TRM 95% CI Gray Test, P
sjTRECs pre-HSCT .46
<50th percentile 3% (0-23)
>50th percentile 7% (2-28)
sjTRECs þ90 days .60
<50th percentile 7% (2-25)
>50th percentile 4% (0-26)
sjTRECs þ180 days .10
<50th percentile 11% (4-32)
>50th percentile 0
sjTRECs þ365 days .17
<50th percentile 10% (1-37)
>50th percentile 0
sjTREC level showed no statistically signiﬁcant correlation (P < .05) with
TRM at any time point considered.
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to 100%), and 83% (95% CI, 63% to 100%) respectively; these
differences were statistically signiﬁcant (P ¼ .009).
Considering OS at 2 years, we found a difference accord-
ing to pre-HSCT sjTREC levels: Patients with sjTREC levels
under the median value of the study population had an OS
rate of 73% (95% CI, 57% to 89%), whereas patients with
sjTREC levels over the median value of the study population
had an OS rate of 89% (95% CI, 57% to 89%), although this
difference was not statistically signiﬁcant (P ¼ .13). Restrict-
ing 2-year OS analysis according to pre-HSCT sjTREC levels
only to the cohort of patients affected by malignant diseases,
we also highlighted a difference, but it was not statistically
signiﬁcant (P ¼ .14).
Female patients showed better OS compared with male
patients (89% [95% CI, 75% to 100%] versus 60% [95% CI, 44% to
76%], P ¼ .035), and patients in an early disease phase had
better OS compared with patients in advanced disease pha-
ses (100% versus 60% [95% CI, 44% to 76%], P ¼ .04). All other
variables investigated in the univariate analysis (Table 3)
showed no correlation with OS. In particular, we did not
observe a correlation between OS or sjTREC levels
at þ90, þ180, and þ365 days after HSCT (Table 3).
To performmultivariate analysis, we selected from among
variables listed in Table 3, those reaching P < .1 in the uni-
variate analysis (sex, comorbidities, disease phase at HSCT,
and pre-HSCT sjTREC levels). In the multivariate analysis,
sjTREC levels before transplantation and pre-HSCT comor-
bidities were the only variables we found to be associated
with OS: Patients with higher sjTRECs values showed a sta-
tistically signiﬁcant reduced risk of death compared with
patients with lower sjTRECs values (relative risk, .49; 95% CI,
.48 to .5; P¼ .03), and patients in the intermediate-risk group
(score 1 to 2) according to Smith et al. [18] showed a statis-
tically signiﬁcant increased risk of death compared with pa-
tients in the low-risk group (score 0) (relative risk, 2.5; 95% CI,
2.49 to 2.5; P ¼ .03). In multivariate analysis sex and disease
phase showedno statistically signiﬁcant relationshipwithOS.
Transplant-Related Mortality
The overall TRM was 5% (95% CI, 2% to 16%). In the uni-
variate analysis sjTREC levels before transplantation and
sjTREC levels at þ90 days did not show any correlation withthe TRM. At þ180 days from transplant, patients with
sjTRECs values under the 50th percentile had a TRM rate of
11% (95% CI, 4% to 32%) versus a TRM rate of 0 of patients with
sjTREC values over the 50th percentile. Likewise, at þ365
days patients with sjTREC values under the 50th percentile
had a TRM rate of 10% (95% CI, 1% to 37%) versus a TRM of 0 in
patients with sjTREC values over the 50th percentile. These
differences in terms of TRM were not statistically signiﬁcant
(P ¼ .1 and P ¼ .17, respectively) (Table 4).
Relapse Incidence
For malignant disease, the overall RI was 30% (95% CI, 20%
to 46%). sjTREC levels before transplantation were related
to relapse. Patients with sjTREC levels below the 50th
percentile of the study population relapsed in 43% of cases
(95% CI, 28% to 66%), whereas 14% of patients with sjTREC
levels above the 50th percentile experienced a relapse (95%
CI, 5% to 41%); this difference was statistically signiﬁcant (P¼
.02) (Table 4 and Figure 2).
Considering sjTREC levels before the transplant sub-
grouped in quartiles, patients with sjTREC levels in the ﬁrst,
second, third, and fourth quartiles had a relapse in 64% (95%
CI, 43% to 95%), 21% (95% CI, 8% to 58%), 14% (95% CI, 4% to
51%), and 14% (95% CI, 2% to 88%) of cases, respectively, and
this difference was statistically signiﬁcant (P ¼ .01). sjTREC
levels at þ90, þ180, and þ365 days were not related to the
recurrence.
Among other variables investigated by univariate anal-
ysis, patient gender showed a relationship with RI: Male
patients relapsed in 40% (95% CI, 27% to 60%), whereas female
patients relapsed in 7% (95% CI, 1% to 47%; P ¼ .03) (Table 5).
To perform multivariate analysis, we selected, from among
the variables listed in Table 5, those reaching P < .1 in
the univariate analysis (sex and pre-HSCT sjTREC levels) and
disease phase at HSCT. In the multivariate analysis sjTREC
levels before transplantation were the only variables we
found to be statistically associated (relative risk, 0; P< .0001)
with RI.
Chimerism and Immune Recovery
All patients showed sustained engraftment, and we did
not observe any cases of either early or late graft loss. Pa-
tients enrolled in the study reached the ﬁfth percentile of
normal lymphocyte values for patient age in a median of 70
days (range, 21 to 420), with no differences related to pre-
HSCT sjTREC levels: 73 days (range, 25 to 420) for patients
with sjTRECs over the 50th percentile before HSCT versus 65
days (range, 21 to 385) for patients with sjTRECs under the
Table 5
RI for Malignant Diseases: Univariate Analysis
Variable n Events RI 95% CI Gray
Test, P
sjTRECs pre-HSCT .02
<50th percentile 28 12 43% (28-66)
>50th percentile 19 3 14% (5-41)
sjTRECs þ90 days .60
<50th percentile 26 7 26% (14-49)
>50th percentile 21 8 33% (18-61)
sjTRECs þ180 days
<50th percentile 27 10 37% (15-52) .34
>50th percentile 20 5 25% (5-46)
sjTRECs þ365 days .36
<50th percentile 11% (3-41)
>50th percentile 23% (8-62)
Sex .03
Male 34 14 41% (27-61)
Female 13 1 8% (1-50)
Age .58
0-5 yr 12 4 33% (14-69)
6-8 yr 8 4 50% (21-92)
9-14 yr 15 3 20% (7-55)
>15 yr 12 4 33% (15-74)
Disease phase .20
Early 8 1 12% (2-78)
Advanced 39 14 35% (22-52)
Time between diagnosis
and HSCT
.67
<6 mo 25 7 28% (15-52)
>6 mo 22 8 36% (21-63)
HSC source .29
BM 39 14 36% (24-55)
CB 7 1 14% (2-87)
PBSC 1 0 0
Donor .24
Related 17 7 41% (23-73)
Unrelated 30 8 27% (15-48)
Acute GVHD .41
Yes 20 5 25% (12-53)
No 27 15 37% (23-60)
Chronic GVHD
Yes 8 2 25% (7-83) .57
No 39 13 32% (20-50)
Univariate analysis of variables potentially able to inﬂuence RI: sjTRECs
before the transplantation and patient’s sex were statistically related to RI
incidence (P < .05).
Figure 2. Relapse rate according to sjTREC levels. Patients with sjTRECs over
the 50th percentile before HSCT (continuous line) showed a statistically sig-
niﬁcant reduced relapse rate compared with patients with sjTRECs under the
50th percentile (dotted line) at same time point.
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populations, the proportion of patients who reached the ﬁfth
percentile of normal values for their ages of CD3þCD4þ,
CD3þCD8þ, CD16þCD56þ, and CD19þCD20þ cells was 17%,
65%, 82%, and 60% at day þ180 and 70%, 85%, 88%, and 77% at
day þ365, respectively, with no differences related to pre-
HSCT sjTREC levels.
DISCUSSION
T cell function recovery has been shown to be 1 of the
most important factors in determining the prognosis of
patients undergoing alloHSCT, and the role of the thymus in
this process is well established. Previous studies focused on
severe combined immunodeﬁciency disease screening pro-
grams in newborns [26] and on the management of patients
affected by HIV and undergoing highly active antiretroviral
therapy [27] indicated that sjTREC quantiﬁcation is an easy,
sensible, and reliable technique to evaluate immunologic
function and also to drive therapeutic interventions in these
settings. Although the experience of alloHSCT is more
limited, there is growing evidence that sjTREC quantiﬁcation
by PCR is 1 of the easiest and most reliable methods to
evaluate thymic activity after alloHSCT as well. This is
because, compared with other techniques (ie, ﬂow cytom-
etry), this method offers the advantage of not being inﬂu-
enced by any phenomena that typically occur after
transplantation, such as the opportunity of T memory cells to
revert into a T naive phenotype, as in case of recurrent herpes
virus infection [28]; the possibility of T naive cells to main-
tain their phenotype while acquiring T memory cells’ func-
tion [29]; and the maintenance of CD31 expression during
CD4þ cell cytokine-driven proliferation [30].
Even though other studies have already shown a corre-
lation between sjTREC levels and the various phases of im-
mune recovery after alloHSCT [10-12] and that patients with
a more efﬁcient thymic function show a better prognosis
compared with others [13,31], there are still very few studies
speciﬁcally concerning pediatric patients. Considering aging
is a major parameter impacting thymic function [9,32],
childhood may be considered an ideal setting to further
consolidate these data. In the present study we analyzed in a
population of pediatric patients undergoing alloHSCT therole of sjTREC levels on OS and found that patients withmore
efﬁcient thymic function before transplantation had better
long-term OS compared with others. However, sjTREC levels
after transplantation, according to our data, did not have any
inﬂuence on OS at any of the time points considered.
To our knowledge only 2 previous studies speciﬁcally
investigated the impact of sjTRECs on OS. Clave et al. [17]
demonstrated a correlation between pretransplantation
sjTREC levels and OS, but even though a high number of cases
were reported (n ¼ 102), only sibling recipients were
included, the patients’ median age was higher, and only
pretransplantation sjTREC levels were considered. In 66 pe-
diatric patients who underwent alloHSCT, Olkinuora et al.
[33] reported a shorter median survival time for patients
with low sjTREC levels at different time points (both before
and after alloHSCT) comparedwith patients with high sjTREC
levels, but their study lacked a real survival analysis per-
formed with the Kaplan-Meier method and the follow-up
was shorter. We basically conﬁrmed a correlation between
sjTREC levels and OS in a more homogeneous and younger
population that also included unrelated transplant re-
cipients, and by extending the follow-up to a median time of
72 months, we highlighted that among pediatric patients
F. Saglio et al. / Biol Blood Marrow Transplant 21 (2015) 1099e11051104long-term survival is closely related to pre-HSCT sjTREC
levels. However, a limitation of our study is that a large
proportion of the patients enrolled in our study had acute
lymphoblastic leukemia, which tends to undergo relapse in
the ﬁrst months after transplantation; therefore, the corre-
lation between sjTREC levels and OS seems to be less strong
in the short term. Moreover, the small number of patients
affected by nonmalignant disorders included in the study
population might be also responsible for the absence of a
statistically signiﬁcant association between 2-year OS and
pre-HSCT sjTREC levels.
To understand whether the mortality reduction we
observed was attributable to a reduction of either TRM or RI,
we analyzed in the same population the impact of sjTREC
levels on these 2 outcome parameters. In line with other
authors’ ﬁndings, we observed a strong correlation between
pretransplantation thymic functions and RI [15,16]. However,
unlike these authors, who investigated the role of sjTRECs in
only 1 speciﬁc setting, surprisingly, we did not observe a
correlation between post-transplantation thymic activity
and RI. This difference might be related to the heterogeneity
of our study population that included bone marrow, pe-
ripheral blood stem cells, and cord blood recipients. One
possible objection to our observations could be that reduced
sjTREC frequency before alloHSCT might be related to more
intense treatments administered because of a more aggres-
sive disease and that OS and RI differences might only be
related to a more advanced disease phase. However, via
multivariate analysis, we were able to show how sjTREC
levels before transplantation are statistically associated with
OS and RI independently from other variables, including the
presence of an advanced disease phase. By correlation anal-
ysis, we excluded a link between the disease phase at
transplantation and the time between diagnosis and HSCT
and sjTREC frequency before alloHSCT. In multivariate anal-
ysis we found the only other variable associated with OS was
the presence of comorbidities as scored by Smith et al. [18].
Unlike previous observations [7,13,14,33,34], we did not
observe a relationship between sjTRECs and TRM, probably
because of the very low incidence of these complications in
our study population related to the lower frequency of
comorbidities in young individuals.
Finally, to clarify whether increased OS and reduced RI of
patients with higher pre-HSCT sjTREC levels were related to
an improved immune recovery, we evaluated the absolute
lymphocyte count recovery. Surprisingly, we did not observe
any differences between the patients with values over the
50th percentile or patients with values under the 50th
percentile. Our data contrast with previous reports [12], but
this might be because of our smaller sample size and might
be related to the differences in the recovery of different
lymphocyte subsets (T, B, natural killer) after HSCT. By
analyzing transplant-related factors that inﬂuence sjTREC
frequency, we conﬁrmed previously reported observations
on adults [35] conﬁrming GVHD as 1 of the most limiting
factors in determining sjTREC levels after transplantation.
However, according to our analysis, sjTREC reductions after
HSCT were not statistically correlated with any worsening in
terms of OS, TRM, or relapse.
The main weakness of our study is that we analyzed
sjTREC frequency on whole PBMCs, whereas other authors
performed the same analysis more precisely on selected
lymphocyte populations (ie, CD3þ, CD3þCD4þ, CD3þCD8þ).
Another limitation of our study is that in the series of
patients we described, most were affected by acutelymphoblastic leukemia, but no cases of T cell leukemia were
included; this may have some consequences in terms of both
RI and OS.
In conclusion, our results conﬁrm that thymic function
does play an important role in determining the prognosis of
pediatric patients undergoing alloHSCT, suggesting an efﬁ-
cient thymic function before transplantation is related to
improved long-term OS, mainly through a reduction of
relapse opportunities. Obviously, larger and more accurate
studies are needed both to conﬁrm these observations and to
identify the mechanism driving them to ﬁnd solutions aimed
at improving T cell recovery after alloHSCT.ACKNOWLEDGMENTS
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